登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
ClinicalTrials.gov 上登记的一项鼻咽癌开放试验。牵头方不是本站收录的医院;本站收录的 5 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 5
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心中山大学附属第五医院Fifth Affiliated Hospital of Sun Yat-sen University珠海医院页面
- 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
- 研究中心梧州市红十字会医院Wuzhou Red Cross Hospital梧州医院页面
- 研究中心粤北人民医院Yuebei People's Hospital韶关医院页面
- 研究中心中山市人民医院Zhongshan City People's Hospital中山医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT04453813,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 9
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(9 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
Histologically confirmed recurrent nasopharyngeal carcinoma.
入选标准第 1 条
Tumor staged as rT2-4N0-3M0,rII-IVa (according to the 8th AJCC edition).
入选标准第 3 条
Resectable nasopharyngeal diseases: rT2 (the tumour is confined in the superficial parapharyngeal spacer and is more than 0.5cm from the internal carotid artery) and rT3 (the tumour is confined in the base wall of the sphenoid sinus and is more than 0.5cm from the internal carotid artery and cavernous sinus).
排除标准第 1 条
The recurrence time is more than 12 months from the end of the first course of radiotherapy.
入选标准第 2 条
Received a systematic glucocorticoid therapy within 4 weeks of the first dose of study medication.
排除标准第 8 条
Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent.
排除标准第 10 条
Karnofsky scale (KPS)≥70.
入选标准第 5 条
total bilirubin, AST and ALT levels of no more than 2.5 times the upper normal limit;
入选标准第 8 条
creatinine clearance rate of at least 60 mL/min or creatinine of no more than 1.5 times the upper normal limit.
入选标准第 9 条
Subjects must have a measurable disease by CT or MRI per RECIST 1.1 criteria.
入选标准第 4 条
Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB with 1 year.
排除标准第 9 条
Has a known history of human immunodeficiency virus (HIV).
排除标准第 12 条
Has hepatitis B surface antigen (HBsAg) positive with HBV DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive
排除标准第 13 条
Pregnancy or breast feeding
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04453813,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Histologically confirmed recurrent nasopharyngeal carcinoma. The recurrence time is more than 12 months from the end of the first course of radiotherapy. Tumor staged as rT2-4N0-3M0,rII-IVa (according to the 8th AJCC edition). Subjects must have a measurable disease by CT or MRI per RECIST 1.1 criteria. Karnofsky scale (KPS)≥70. Normal bone marrow function. Normal liver and kidney function: total bilirubin, AST and ALT levels of no more than 2.5 times the upper normal limit; creatinine clearance rate of at least 60 mL/min or creatinine of no more than 1.5 times the upper normal limit. Given written informed consent.排除标准:Exclusion Criteria:
Resectable nasopharyngeal diseases: rT2 (the tumour is confined in the superficial parapharyngeal spacer and is more than 0.5cm from the internal carotid artery) and rT3 (the tumour is confined in the base wall of the sphenoid sinus and is more than 0.5cm from the internal carotid artery and cavernous sinus). The patients are suffering from severe nasopharyngeal necrosis, radiation induced brain injury, and fibrosis of the neck et. al, who are evaluated as unsuitable for secondary radiotherapy by the researchers. Has known allergy to large molecule protein products or any compound of study therapy. Has known subjects with other malignant tumors. Has any active autoimmune disease or history of autoimmune disease. Has a history of psychiatric substance abuse, alcoholism, or drug addiction. The laboratory examination value does not meet the relevant standards within 7 days before enrollment Received a systematic glucocorticoid therapy within 4 weeks of the first dose of study medication. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB with 1 year. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy). Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) will be allowed to enroll. Has a known history of human immunodeficiency virus (HIV). Has hepatitis B surface antigen (HBsAg) positive with HBV DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive Has received a live vaccine within 4 weeks of planned start of study therapy Pregnancy or breast feeding
引自 ClinicalTrials.gov, NCT04453813, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04453813,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。